Abstracts tagged "risk factors"

Abstract Number: 0067 • ACR Convergence 2024
Psoriasis Patients at Risk for Psoriatic Arthritis Have Increased Levels of Circulating Pro-migratory Dendritic Cells
Shashank Cheemalavagu, Unnikrishnan Chandrasekharan, Oliver Wessely, Uyen Tran and M. Elaine Husni, Cleveland Clinic, Cleveland, OH
Background/Purpose: Early diagnosis of Psoriatic Arthritis (PsA) is critical for timely intervention to prevent poor clinical outcomes. Despite well-known clinical predictors of PsA, the mechanisms…
Abstract Number: 0674 • ACR Convergence 2024
Hydroxychloroquine Screening Adherence: Insights from Highmark Claims Data
Sara Shahid¹, Tyson Barrett², Sonia Manocha¹ and Tanmayee Bichile¹, ¹Allegheny Health Network, Pittsburgh, PA, ²Highmark Health, Pittsburgh, PA
Background/Purpose: Hydroxychloroquine (HCQ)-associated retinal toxicity and vision loss are significant challenges, with a 2% prevalence in patients using HCQ for over 10 years and up…
Abstract Number: 1004 • ACR Convergence 2024
Predictors of Post-acute Sequelae of COVID-19 in Patients with Rheumatoid Arthritis: A Retrospective Analysis of a Large Health System in the Midwestern United States
Ernesto Lopez Castillo¹ and Jeffrey Ording², ¹University of Colorado, Denver, CO, ²Advocate Illinois Masonic Medical Center, Chicago, IL
Background/Purpose: Evidence suggests that patients with autoimmune diseases or immunosuppressive conditions have a higher risk of poor outcomes related to Coronavirus disease 2019 (COVID-19) infection.…
Abstract Number: 1871 • ACR Convergence 2024
A Seropositive RA Polygenic Risk Score Does Not Predict Progression to RA in an ACPA Positive Population
Tada Vargas¹, Lauren Vanderlinden², Patrick Carry³, Kristen Demoruelle⁴, Marie Feser¹, Katerina Kechris⁵, Jane Buckner⁶, William Robinson⁷, Gary Firestein⁸, Michael Holers¹, Kevin Deane⁹ and Jill Norris¹⁰, ¹Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ²Colorado School of Public Health, Monument, CO, ³Department of Orthopedics, University of Colorado School of Medicine, Aurora, CO, ⁴University of Colorado Anschutz Medical Campus, Golden, CO, ⁵Department of Biostatistics and Informatics, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, ⁶Benaroya Research Institute, Seattle, WA, ⁷Division of Immunology and Rheumatology, Stanford University, and VA Palo Alto Health Care System, Stanford, CA, ⁸University of California, San Diego, San Diego, CA, ⁹University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ¹⁰Colorado School of Public Health, Denver, CO
Background/Purpose: Serum autoantibodies, such as ACPA and RF, are commonly detectable prior to the development of seropositive clinical RA; however, not all individuals with these…
Abstract Number: 2469 • ACR Convergence 2024
Machine Learning Identifies Oesophageal Symptoms as a New Red Flag for for Very Early Diagnosis of Systemic Sclerosis (VEDOSS): A EUSTAR Analysis
Stefano Di Donato¹, Vishal Kakkar², Silvia Bellando-Randone³, Marco Matucci-Cerinic⁴ and Francesco Del Galdo², and EUSTAR collaborators, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, ²University of Leeds, Leeds, United Kingdom, ³University of Florence, Florence, Florence, Italy, ⁴University San Raffaele Milano, Milano, Milan, Italy
Background/Purpose: The analysis of the EUSTAR Very Early Diagnosis of Systemic Sclerosis (VEDOSS) study has identified the risk of progression to fulfil 2013 ACR/EULAR classification…
Abstract Number: 0108 • ACR Convergence 2024
Phenotypic Characterization of Patients with IgM Antibodies in Antiphospholipid Syndrome (APS)
Fernanda Oliveira de Andrade Lopes¹, Andreia Coimbra Sousa², Massimo Radin³, Gustavo Balbi⁴, Irene Cecchi³, Savino Sciascia⁵, Flavio Victor Signorelli⁶ and Danieli Andrade², ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ²University of São Paulo, São Paulo, SP, Brazil, ³University of Turin, Turin, Italy, ⁴Universidade Federal de Juiz de Fora, Juiz de Fora, Minas Gerais, Brazil, ⁵University of Turin, Torino, Turin, Italy, ⁶Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Brazil
Background/Purpose: Antiphospholipid syndrome (APS) is characterized by the presence of antiphospholipid antibodies (aPL) associated with thrombosis and/or pregnancy morbidity. Although the presence of lupus anticoagulant…
Abstract Number: 0695 • ACR Convergence 2024
Prognostic Value of Serum Type I Interferon in Predicting Morbi-Mortality Outcomes in Systemic Sclerosis: Insights from the STRIKE Basket Cohort
Stefano Di Donato¹, Marco Minerba², Enrico De Lorenzis³, Collette Hartley⁴, Lesley-Anne Bissell⁵, Rebecca Ross⁶ and Francesco Del Galdo⁴, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, ²Campus Bio-Medico University of Rome, Taranto, United Kingdom, ³Catholic University of the Sacred Heart, Roma, Rome, Italy, ⁴University of Leeds, Leeds, United Kingdom, ⁵Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁶Medicine and Health, University of Leeds, Leeds, United Kingdom
Background/Purpose: Systemic Sclerosis (SSc) encompasses limited cutaneous (lc)SSc and diffuse cutaneous (dc)SSc, with lcSSc affecting more than 60% of patients and dcSSc associated being burdened…
Abstract Number: 1007 • ACR Convergence 2024
Demographic, Social, and Disease Factors Associated with Interstitial Lung Disease and Disease-Related Death in Dermatomyositis
Connor Buechler, Lindsey Wanberg, Nawang Singhe, Cody Rasner, Joseph McGrath, Ziou Jiang, Karen Baker-James and David Pearson, University of Minnesota, Minneapolis, MN
Background/Purpose: Dermatomyositis (DM) is associated with significant morbidity and mortality due to disease-related progressive interstitial lung disease (ILD) and malignancy. However, little is known about…
Abstract Number: 1883 • ACR Convergence 2024
Psoriatic Arthritis Flare Incidence, Definitions and Risk Factors: A Systematic Review
Batoul Hojeij¹, Gonul Hazal Koc², Jolanda Luime¹, Marijn Vis¹, Marc R. Kok³ and Ilja Tchetverikov⁴, ¹Erasmus MC, Rotterdam, Netherlands, ²Erasmus MC, Rotterdam, Zuid-Holland, Netherlands, ³Maasstad Hospital, Rotterdam, Netherlands, ⁴Albert Schweitzer Hospital, Dordrecht, Netherlands
Background/Purpose: Combined assessment of psoriatic arthritis (PsA) flare incidence and risk factors has not been conducted before, leading to challenges in effective flare management, especially…
Abstract Number: 2486 • ACR Convergence 2024
Glucocorticoids May Mitigate the Risk of Avacopan-Induced Liver Dysfunction in ANCA-Associated Vasculitis: Data from a Multicenter Observational Study in Japan
Tomohisa Uchida¹, Shoichi Fukui¹, Naoki Iwamoto¹, Ayaka Umetsu², Momoko Okamoto², Keita Fujikawa², Akinari Mizokami², Takuya Tomokawa³, Kazusato Hara³, Yoshiro Horai³ and Atsushi Kawakami⁴, ¹Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Department of Rheumatology, Japan Community Healthcare Organization (JCHO) Isahaya General Hospital, Isahaya, Japan, ³Department of Rheumatology, Sasebo City General Hospital, Sasebo, Japan, ⁴Nagasaki University, Nagasaki, Japan
Background/Purpose: Avacopan, a C5a receptor inhibitor, has emerged as a novel treatment for ANCA-associated vasculitis (AAV), providing an alternative to glucocorticoids1. Despite its promising potential,…
Abstract Number: 0134 • ACR Convergence 2024
Use of Oral Contraceptives in Females with Rheumatoid Arthritis Is Not Associated with an Increased Risk of Venous Thromboembolism: United Kingdom-population Based Study
James Galloway¹, Victoria Basey², Anna Barkaway³, Simon de Lusignan⁴ and Maya H. Buch⁵, ¹Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ²Pfizer UK, Tadworth, United Kingdom, ³Pfizer, Tadworth, United Kingdom, ⁴Royal College of General Practitioners Research and Surveillance Centre, Oxford, United Kingdom, ⁵Division of Musculoskeletal & Dermatological Sciences, University of Manchester, and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom
Background/Purpose: While the use of oral contraceptives in females with immune mediated inflammatory diseases such as rheumatoid arthritis (RA) is acknowledged as a risk factor…
Abstract Number: 0705 • ACR Convergence 2024
Identification of Risk Factors for Incident Cardiomyopathy in Patients with Systemic Sclerosis
Ji Soo Kim¹, Rachel Wallwork¹, Carrie Richardson², Adrianne Woods³, Monica Mukherjee⁴, Steven Hsu⁴, Julie Paik¹, Christopher Mecoli¹, Laura Hummers⁵, Fredrick Wigley⁶, Scott Zeger¹ and Ami Shah⁷, ¹Johns Hopkins University, Baltimore, MD, ²Northwestern University, Chicago, ³Johns Hopkins University Division of Rheumatology, Baltimore, MD, ⁴Johns Hopkins University Division of Cardiology, Baltimore, MD, ⁵Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Ellicott City, MD, ⁶Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Baltimore, MD, ⁷Division of Rheumatology, Johns Hopkins University, Ellicott City, MD
Background/Purpose: Cardiac involvement in systemic sclerosis (SSc) is one of the leading causes of scleroderma-associated death. There are limited data examining risk factors for incident…
Abstract Number: 1035 • ACR Convergence 2024
Impact in Clinical Practice of the European Medicines Agency Health Alert About the Restriction of the Use of JAK Inhibitors
Elisabet Castañeda Estévez¹, Cristina Vergara Dangond¹, Martina Steiner¹, Maria Beatriz Paredes Romero¹, Ana Esteban Vázquez¹, Tatiana Cobo Ibañez¹, Laura Trives Folguera¹, Maria Liz Romero Bogado¹, Isabel De La Cámara Fernandez¹, Patricia Richi Alberti¹, Ana Valeria Acosta Alfaro², Iria De La Osa Subtil³ and Santiago Muñoz Fernández⁴, ¹Department of Rheumatology. Hospital Universitario Infanta Sofía., Madrid, Spain, ²Hospital Universitario Infanta Sofía., Madrid, Spain, ³Department of Medicine, Faculty of Biomedical and Health Sciences, European University of Madrid., Madrid, Spain, ⁴Hospital Universitario Infanta Sofía. Universidad Europea de Madrid, Madrid, Spain
Background/Purpose: Recently, the European Medicines Agency (EMA) published a health alert that extended to all JAK inhibitors (JAKi) due to a possible class effect, recommending…
Abstract Number: 1888 • ACR Convergence 2024
Anti-Spike Antibodies Protect Against COVID-19 Infection in Immune-Mediated Inflammatory Diseases: Findings from the SUCCEED Study
Jeremiah Tan¹, J. Antonio Avina-Zubieta², Paul Fortin³, Anne-Claude Gingras⁴, Maggie Larche⁵, Dawn Bowdish⁵, Claudie Berger⁶, Ines Colmegna⁷, Carol Hitchon⁸, Diane Lacaille², Dawn Richards⁹, Nadine Lalonde¹⁰, Ayesha Kirmani¹, Jennifer Lee¹¹ and Sasha Bernatsky⁶, ¹Arthritis Research Canada, Vancouver, BC, Canada, ²Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ³Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ⁴Lunenfeld-Tanenbaum Research Institute, Toronto, ON, Canada, ⁵McMaster University, Hamilton, ON, Canada, ⁶Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁷The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹Canadian Arthritis Patients Alliance, Toronto, ON, Canada, ¹⁰COVID-19 Global Rheumatology Alliance, London, ON, Canada, ¹¹The Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: People with immune-mediated inflammatory diseases (IMIDs) may be more vulnerable to severe COVID-19 outcomes. COVID-19 vaccination is a key element in mitigating this risk.…
Abstract Number: 2499 • ACR Convergence 2024
Description of Patients with Kawasaki Disease Shock Syndrome at a Large Tertiary Center
Jessica Nguyen¹, Danielle Guffey², Andrea Ramirez¹, Jamie Lai³, Tiphanie Vogel¹, S. Kristen Sexson Tejtel¹, Cagri Yildirim-Toruner⁴ and Marietta De Guzman¹, ¹Baylor College of Medicine, Houston, TX, ²Baylor College of Medicine, Houston, ³Baylor College of Medicine, The Woodlands, TX, ⁴Baylor College of Medicine/ Texas Children's Hospital, Houston, TX
Background/Purpose: Kawasaki disease shock syndrome (KDSS) is a phenotype of Kawasaki disease (KD) associated with higher rates of refractory KD (RKD) and coronary artery aneurysms…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.